153
Participants
Start Date
August 11, 2011
Primary Completion Date
April 24, 2019
Study Completion Date
June 14, 2019
Metformin XR plus placebo
Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
Metformin XR plus liraglutide
Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
Woman's Hospital, Baton Rouge
Collaborators (1)
Novo Nordisk A/S
INDUSTRY
Woman's
OTHER